nodes	percent_of_prediction	percent_of_DWPC	metapath
Perflutren—Dyspnoea—Teniposide—lymphatic system cancer	0.00342	0.00342	CcSEcCtD
Perflutren—Oedema—Fludarabine—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Perflutren—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Perflutren—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Perflutren—Vomiting—Mechlorethamine—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Perflutren—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Perflutren—Rash—Mechlorethamine—lymphatic system cancer	0.00328	0.00328	CcSEcCtD
Perflutren—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00328	0.00328	CcSEcCtD
Perflutren—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Perflutren—Flushing—Bleomycin—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Perflutren—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Perflutren—Feeling abnormal—Teniposide—lymphatic system cancer	0.00316	0.00316	CcSEcCtD
Perflutren—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Perflutren—Chills—Bleomycin—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Perflutren—Nausea—Mechlorethamine—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Perflutren—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Perflutren—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Perflutren—Haemoglobin—Carmustine—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Perflutren—Urticaria—Teniposide—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Perflutren—Haemorrhage—Carmustine—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Perflutren—Abdominal pain—Teniposide—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Perflutren—Body temperature increased—Teniposide—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Perflutren—Erythema—Bleomycin—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Perflutren—Paraesthesia—Fludarabine—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Perflutren—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Perflutren—Dyspnoea—Fludarabine—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Perflutren—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Perflutren—Dyspepsia—Fludarabine—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Perflutren—Visual impairment—Carmustine—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Perflutren—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Perflutren—Fatigue—Fludarabine—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Perflutren—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Perflutren—Pain—Fludarabine—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Perflutren—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Perflutren—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Perflutren—Eye disorder—Carmustine—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Perflutren—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Perflutren—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Perflutren—Hypersensitivity—Teniposide—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Perflutren—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Perflutren—Flushing—Carmustine—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Perflutren—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Perflutren—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Perflutren—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00278	0.00278	CcSEcCtD
Perflutren—Asthenia—Teniposide—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Perflutren—Malaise—Bleomycin—lymphatic system cancer	0.00273	0.00273	CcSEcCtD
Perflutren—Pruritus—Teniposide—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Perflutren—Arrhythmia—Carmustine—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Perflutren—Leukopenia—Bleomycin—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Perflutren—Cardiac disorder—Vincristine—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Perflutren—Body temperature increased—Fludarabine—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Perflutren—Erythema—Carmustine—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Perflutren—Cough—Bleomycin—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Perflutren—Angiopathy—Vincristine—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Perflutren—Diarrhoea—Teniposide—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Perflutren—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Perflutren—Chest pain—Bleomycin—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Perflutren—Myalgia—Bleomycin—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Perflutren—Coma—Methotrexate—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Perflutren—Back pain—Carmustine—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Perflutren—Discomfort—Bleomycin—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Perflutren—Chills—Mitoxantrone—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Perflutren—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Perflutren—Vision blurred—Carmustine—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Perflutren—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Perflutren—Tremor—Carmustine—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Perflutren—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Perflutren—Oedema—Bleomycin—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Perflutren—Erythema—Mitoxantrone—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Perflutren—Back pain—Vincristine—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Perflutren—Vomiting—Teniposide—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Perflutren—Agitation—Carmustine—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Perflutren—Asthenia—Fludarabine—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Perflutren—Rash—Teniposide—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Perflutren—Dermatitis—Teniposide—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Perflutren—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Perflutren—Headache—Teniposide—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Perflutren—Pruritus—Fludarabine—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Perflutren—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Perflutren—Back pain—Mitoxantrone—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Perflutren—Leukopenia—Carmustine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Perflutren—Agitation—Vincristine—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Perflutren—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Perflutren—Hypotension—Bleomycin—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Perflutren—Diarrhoea—Fludarabine—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Perflutren—Convulsion—Carmustine—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Perflutren—Hypertension—Carmustine—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Perflutren—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Perflutren—Nausea—Teniposide—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Perflutren—Vertigo—Vincristine—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Perflutren—Leukopenia—Vincristine—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Perflutren—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Perflutren—Myalgia—Carmustine—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Perflutren—Chest pain—Carmustine—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Perflutren—Paraesthesia—Bleomycin—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Perflutren—Malaise—Mitoxantrone—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Perflutren—Dyspnoea—Bleomycin—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Perflutren—Leukopenia—Mitoxantrone—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Perflutren—Convulsion—Vincristine—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Perflutren—Hypertension—Vincristine—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Perflutren—Oedema—Carmustine—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Perflutren—Myalgia—Vincristine—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Perflutren—Visual disturbance—Methotrexate—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Perflutren—Cough—Mitoxantrone—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Perflutren—Vomiting—Fludarabine—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Perflutren—Convulsion—Mitoxantrone—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Perflutren—Rash—Fludarabine—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Perflutren—Dermatitis—Fludarabine—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Perflutren—Hypertension—Mitoxantrone—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Perflutren—Pain—Bleomycin—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Perflutren—Headache—Fludarabine—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Perflutren—Tachycardia—Carmustine—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Perflutren—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Perflutren—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Perflutren—Myalgia—Mitoxantrone—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Perflutren—Chest pain—Mitoxantrone—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Perflutren—Discomfort—Mitoxantrone—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Perflutren—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Perflutren—Oedema—Vincristine—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Perflutren—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Perflutren—Nervous system disorder—Vincristine—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Perflutren—Hypotension—Carmustine—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Perflutren—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Perflutren—Oedema—Mitoxantrone—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Perflutren—Nausea—Fludarabine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Perflutren—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Perflutren—Shock—Mitoxantrone—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Perflutren—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Perflutren—Urticaria—Bleomycin—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Perflutren—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Perflutren—Body temperature increased—Bleomycin—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Perflutren—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Perflutren—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Perflutren—Paraesthesia—Carmustine—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Perflutren—Hypotension—Vincristine—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Perflutren—Dyspnoea—Carmustine—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Perflutren—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Perflutren—Hypotension—Mitoxantrone—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Perflutren—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Perflutren—Paraesthesia—Vincristine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Perflutren—Pain—Carmustine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Perflutren—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Perflutren—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Perflutren—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Perflutren—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Perflutren—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Perflutren—Feeling abnormal—Carmustine—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Perflutren—Fatigue—Vincristine—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Perflutren—Asthenia—Bleomycin—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Perflutren—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Perflutren—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Perflutren—Pain—Vincristine—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Perflutren—Pruritus—Bleomycin—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Perflutren—Eosinophilia—Methotrexate—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Perflutren—Fatigue—Mitoxantrone—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Perflutren—Pain—Mitoxantrone—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Perflutren—Abdominal pain—Carmustine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Perflutren—Body temperature increased—Carmustine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Perflutren—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Perflutren—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Perflutren—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Perflutren—Body temperature increased—Vincristine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Perflutren—Abdominal pain—Vincristine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Perflutren—Urticaria—Mitoxantrone—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Perflutren—Hypersensitivity—Carmustine—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Perflutren—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Perflutren—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Perflutren—Vomiting—Bleomycin—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Perflutren—Rash—Bleomycin—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Perflutren—Dermatitis—Bleomycin—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Perflutren—Asthenia—Carmustine—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Perflutren—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Perflutren—Hypersensitivity—Vincristine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Perflutren—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Perflutren—Asthenia—Vincristine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Perflutren—Diarrhoea—Carmustine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Perflutren—Nausea—Bleomycin—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Perflutren—Asthenia—Mitoxantrone—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Perflutren—Dizziness—Carmustine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Perflutren—Haemoglobin—Methotrexate—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Perflutren—Diarrhoea—Vincristine—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Perflutren—Haemorrhage—Methotrexate—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Perflutren—Pharyngitis—Methotrexate—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Perflutren—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Perflutren—Vomiting—Carmustine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Perflutren—Dizziness—Vincristine—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Perflutren—Rash—Carmustine—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Perflutren—Dermatitis—Carmustine—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Perflutren—Visual impairment—Methotrexate—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Perflutren—Headache—Carmustine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Perflutren—Eye disorder—Methotrexate—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Perflutren—Tinnitus—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Perflutren—Vomiting—Vincristine—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Perflutren—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Perflutren—Rash—Vincristine—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Perflutren—Dermatitis—Vincristine—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Perflutren—Headache—Vincristine—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Perflutren—Nausea—Carmustine—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Perflutren—Angiopathy—Methotrexate—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Perflutren—Vomiting—Mitoxantrone—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Perflutren—Immune system disorder—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Perflutren—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Perflutren—Rash—Mitoxantrone—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Perflutren—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Perflutren—Chills—Methotrexate—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Perflutren—Headache—Mitoxantrone—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Perflutren—Erythema—Methotrexate—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Perflutren—Nausea—Vincristine—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Perflutren—Dysgeusia—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Perflutren—Nausea—Mitoxantrone—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Perflutren—Back pain—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Perflutren—Vision blurred—Methotrexate—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Perflutren—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Perflutren—Malaise—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Perflutren—Vertigo—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Perflutren—Leukopenia—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Perflutren—Cough—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Perflutren—Convulsion—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Perflutren—Myalgia—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Perflutren—Chest pain—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Perflutren—Arthralgia—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Perflutren—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Perflutren—Discomfort—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Perflutren—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.001	0.001	CcSEcCtD
Perflutren—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000981	0.000981	CcSEcCtD
Perflutren—Skin disorder—Methotrexate—lymphatic system cancer	0.000972	0.000972	CcSEcCtD
Perflutren—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000967	0.000967	CcSEcCtD
Perflutren—Hypotension—Methotrexate—lymphatic system cancer	0.000935	0.000935	CcSEcCtD
Perflutren—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000912	0.000912	CcSEcCtD
Perflutren—Paraesthesia—Methotrexate—lymphatic system cancer	0.000898	0.000898	CcSEcCtD
Perflutren—Dyspnoea—Methotrexate—lymphatic system cancer	0.000892	0.000892	CcSEcCtD
Perflutren—Dyspepsia—Methotrexate—lymphatic system cancer	0.000881	0.000881	CcSEcCtD
Perflutren—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000864	0.000864	CcSEcCtD
Perflutren—Fatigue—Methotrexate—lymphatic system cancer	0.000863	0.000863	CcSEcCtD
Perflutren—Pain—Methotrexate—lymphatic system cancer	0.000856	0.000856	CcSEcCtD
Perflutren—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000825	0.000825	CcSEcCtD
Perflutren—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000818	0.000818	CcSEcCtD
Perflutren—Urticaria—Methotrexate—lymphatic system cancer	0.000795	0.000795	CcSEcCtD
Perflutren—Abdominal pain—Methotrexate—lymphatic system cancer	0.000791	0.000791	CcSEcCtD
Perflutren—Body temperature increased—Methotrexate—lymphatic system cancer	0.000791	0.000791	CcSEcCtD
Perflutren—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000737	0.000737	CcSEcCtD
Perflutren—Asthenia—Methotrexate—lymphatic system cancer	0.000718	0.000718	CcSEcCtD
Perflutren—Pruritus—Methotrexate—lymphatic system cancer	0.000708	0.000708	CcSEcCtD
Perflutren—Diarrhoea—Methotrexate—lymphatic system cancer	0.000685	0.000685	CcSEcCtD
Perflutren—Dizziness—Methotrexate—lymphatic system cancer	0.000662	0.000662	CcSEcCtD
Perflutren—Vomiting—Methotrexate—lymphatic system cancer	0.000636	0.000636	CcSEcCtD
Perflutren—Rash—Methotrexate—lymphatic system cancer	0.000631	0.000631	CcSEcCtD
Perflutren—Dermatitis—Methotrexate—lymphatic system cancer	0.00063	0.00063	CcSEcCtD
Perflutren—Headache—Methotrexate—lymphatic system cancer	0.000627	0.000627	CcSEcCtD
Perflutren—Nausea—Methotrexate—lymphatic system cancer	0.000594	0.000594	CcSEcCtD
